ZURA
NASDAQZura Bio Limited
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
$5.39-0.11 (-2.00%)
News25/Ratings9
Price$5.39+0.10 (+1.89%)
02:00 PM07:45 PM
News · 26 weeks45-40%
2025-10-262026-04-19
Mix3490d
- Insider12(35%)
- SEC Filings11(32%)
- Other5(15%)
- Offering4(12%)
- Analyst1(3%)
- Leadership1(3%)
Latest news
25 items- SECZura Bio Limited filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Zura Bio Ltd (0001855644) (Filer)
- INSIDERSEC Form 4 filed by Davis Kim4 - Zura Bio Ltd (0001855644) (Issuer)
- INSIDERSEC Form 4 filed by Nistala Kiran4 - Zura Bio Ltd (0001855644) (Issuer)
- INSIDERSEC Form 4 filed by Hyllengren Eric J4 - Zura Bio Ltd (0001855644) (Issuer)
- INSIDERSEC Form 4 filed by Whale Gary4 - Zura Bio Ltd (0001855644) (Issuer)
- INSIDERSEC Form 4 filed by Kulkarni Sandeep Chidambar4 - Zura Bio Ltd (0001855644) (Issuer)
- SECSEC Form 10-K filed by Zura Bio Limited10-K - Zura Bio Ltd (0001855644) (Filer)
- SECZura Bio Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Zura Bio Ltd (0001855644) (Filer)
- PRZura Bio Reports Full Year 2025 Financial Results and Recent Corporate UpdatesAdvancing two Phase 2 studies evaluating tibulizumab in hidradenitis suppurativa (HS) and systemic sclerosis (SSc) Topline data expected from the Phase 2 TibuSHIELD study in HS in the fourth quarter of 2026 and from the Phase 2 TibuSURE study in SSc in the first half of 2027 Cash and cash equivalents of $109.4 million as of December 31, 2025 Completed an underwritten public offering in February 2026 for gross proceeds of approximately $144 million; post‑financing cash and cash equivalents expected to support planned operations through at least the end of 2028 Zura Bio Limited (NASDAQ:ZURA) ("Zura"), a clinical‑stage biotechnology company developing novel and differentiated medi
- SECZura Bio Limited filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Zura Bio Ltd (0001855644) (Filer)
- INSIDERSEC Form 4 filed by Director Nirula Ajay4 - Zura Bio Ltd (0001855644) (Issuer)
- INSIDERSEC Form 3 filed by new insider Nirula Ajay3 - Zura Bio Ltd (0001855644) (Issuer)
- SECZura Bio Limited filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Zura Bio Ltd (0001855644) (Filer)
- PRZura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World CongressZura Bio Limited (NASDAQ:ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that the design of its ongoing Phase 2 TibuSURE clinical trial evaluating tibulizumab (ZB-106) in systemic sclerosis (SSc) has been accepted for poster presentation at the Systemic Sclerosis World Congress, taking place March 5–7, 2026 in Athens, Greece. The poster, titled "TibuSURE: A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of
- INSIDERLarge owner Ai Biotechnology Llc bought $12,500,000 worth of Class A Ordinary Shares (2,000,000 units at $6.25) (SEC Form 4)4 - Zura Bio Ltd (0001855644) (Issuer)
- PRZura Bio to Participate in Upcoming Investor ConferencesZura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that members of its management team will participate in the following upcoming investor conferences: Leerink Global Healthcare Conference Location: Miami, FL Fireside chat: Tuesday, March 10, 2026, at 2:20 p.m. ET Investor meetings: Management will meet with investors Jefferies Biotech on the Beach Summit Location: Miami, FL Date: Wednesday, March 11, 2026 Investor meetings: Management will meet with
- PRZura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesZura Bio Limited (NASDAQ:ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that it closed its previously announced underwritten public offering of Class A ordinary shares and pre‑funded warrants on February 26, 2026. The offering consisted of 21,200,000 Class A ordinary shares priced at $6.25 per share, along with pre‑funded warrants for 1,800,000 Class A ordinary shares priced at $6.249 per warrant, which included 3,000,000 additional Class A ordinary shares sold upon exercise in full by the underwriters of th
- SECAmendment: Zura Bio Limited filed SEC Form 8-K: Financial Statements and Exhibits8-K/A - Zura Bio Ltd (0001855644) (Filer)
- SECSEC Form 424B5 filed by Zura Bio Limited424B5 - Zura Bio Ltd (0001855644) (Filer)
- PRZura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded WarrantsZura Bio Limited (NASDAQ:ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the pricing of its previously announced underwritten public offering of 18,200,000 Class A ordinary shares at a price to the public of $6.25 per share and, in lieu of Class A ordinary shares to certain investors that so choose, pre-funded warrants to purchase 1,800,000 Class A ordinary shares at a price to the public of $6.249 per pre-funded warrant, which equals the public offering price per Class A ordinary share, less the $0.001 exercise price o
- INSIDERSEC Form 4 filed by Director Eisner Mark4 - Zura Bio Ltd (0001855644) (Issuer)
- INSIDERSEC Form 3 filed by new insider Eisner Mark3 - Zura Bio Ltd (0001855644) (Issuer)
- SECSEC Form 424B5 filed by Zura Bio Limited424B5 - Zura Bio Ltd (0001855644) (Filer)
- PRZura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded WarrantsZura Bio Limited (NASDAQ:ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that it has commenced an underwritten public offering of its Class A ordinary shares or, in lieu of Class A ordinary shares to certain investors that so choose, pre-funded warrants to purchase Class A ordinary shares. In addition, Zura expects to grant the underwriters a 30-day option to purchase additional Class A ordinary shares in an amount of up to 15% of the aggregate number of shares and shares underlying the pre-funded warrants sold in the o
- SECZura Bio Limited filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Zura Bio Ltd (0001855644) (Filer)